REVVITY, INC. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Revvity reported Q3 2026 pro forma revenue of $710M (+7% organic growth) and pro forma adjusted EPS of $1.37, beating expectations with broad-based growth across both segments (Life Sciences +9% organic, Diagnostics +5% organic). The company raised full-year 2026 pro forma guidance to $2.86B revenue and $5.40–$5.45 adjusted EPS. Separately, Revvity entered a definitive agreement on July 31, 2026 to divest its China Immunodiagnostics business (China IDX, ~6% of FY2025 revenue) for approximately $120M cash consideration, expected to close by end-2027, with pro forma loss on disposition estimated at $55M.
Why this rating
Raised guidance and beat Q3 expectations; organic growth solid (~5–7%). China IDX divestiture (~$114M annualized revenue, <0.9% of company size) is minor. Overall: moderate positive momentum, not transformational.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.